Literature DB >> 8103377

An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs.

S L Handley1, J W McBlane.   

Abstract

The elevated X-maze has strong claims to validity as an animal model of anxiety, both in theoretical basis and drug responses. The model is sensitive to actual and putative anxiolytics, but because insufficient time has elapsed since its discovery, no agent first predicted to be anxiolytic in the elevated X-maze has been brought into general use yet. It has an advantage in detecting anxiolytic and anxiogenic agents under the same operating conditions. The design and execution of experiments with the model is discussed and it is shown that baseline arm preference and the size or direction of drug effects differ in the procedural factors affecting them. Because it presents features of both passive and active avoidance and approach/avoidance conflict, it may prove able to detect drug effects in different forms of human anxiety and aid in understanding their neurobiology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103377     DOI: 10.1016/1056-8719(93)90063-k

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  44 in total

1.  Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats.

Authors:  Leandro J Bertoglio; Antonio P Carobrez
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

2.  Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats.

Authors:  R Spanagel; A Montkowski; K Allingham; T Stöhr; M Shoaib; F Holsboer; R Landgraf
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

3.  The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands.

Authors:  G Griebel; D J Sanger; G Perrault
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

4.  Effects of palatable cafeteria diet on cognitive and noncognitive behaviors and brain neurotrophins' levels in mice.

Authors:  Daniela D Leffa; Samira S Valvassori; Roger B Varela; Jésica Lopes-Borges; Francine Daumann; Luiza M Longaretti; Ana Luiza F Dajori; João Quevedo; Vanessa M Andrade
Journal:  Metab Brain Dis       Date:  2015-05-22       Impact factor: 3.584

5.  Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task.

Authors:  Laila Asth; Nataly Correia; Bruno Lobão-Soares; Thereza C Monteiro De Lima; Remo Guerrini; Girolamo Calo'; Vanessa P Soares-Rachetti; Elaine C Gavioli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-16       Impact factor: 3.000

6.  A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat.

Authors:  W S Redfern; A Williams
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  Anxiolytic activity of adenosine receptor activation in mice.

Authors:  N Jain; N Kemp; O Adeyemo; P Buchanan; T W Stone
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

8.  Cocaine withdrawal-induced anxiety in females: impact of circulating estrogen and potential use of delta-opioid receptor agonists for treatment.

Authors:  Lisa M Ambrose-Lanci; R C Sterling; Elisabeth J Van Bockstaele
Journal:  J Neurosci Res       Date:  2010-03       Impact factor: 4.164

9.  Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats.

Authors:  M D S Lapiz-Bluhm; C O Bondi; J Doyen; G A Rodriguez; T Bédard-Arana; D A Morilak
Journal:  J Neuroendocrinol       Date:  2008-07-30       Impact factor: 3.627

10.  Evaluation of the anxiolytic-like effect of NKP608, a NK1-receptor antagonist, in two rat strains that differ in anxiety-related behaviors.

Authors:  Leandro F Vendruscolo; Reinaldo N Takahashi; Gustavo R Brüske; André Ramos
Journal:  Psychopharmacology (Berl)       Date:  2003-08-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.